Omaxe Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 9:21 am

Competitors of Omaxe Ltd

All Competitor Stocks of Omaxe Ltd

Quarterly Result

Last Updated: August 20, 2025, 6:00 am

Below is a detailed analysis of the quarterly data for Omaxe Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 282.00 Cr.. The value appears to be declining and may need further review. It has decreased from 541.00 Cr. (Mar 2025) to 282.00 Cr., marking a decrease of 259.00 Cr..
• For Expenses, as of Jun 2025, the value is 452.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 647.00 Cr. (Mar 2025) to 452.00 Cr., marking a decrease of 195.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -170.00 Cr.. The value appears to be declining and may need further review. It has decreased from -106.00 Cr. (Mar 2025) to -170.00 Cr., marking a decrease of 64.00 Cr..
• For OPM %, as of Jun 2025, the value is -60.00%. The value appears to be declining and may need further review. It has decreased from -20.00% (Mar 2025) to -60.00%, marking a decrease of 40.00%.
• For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
• For Interest, as of Jun 2025, the value is 67.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 16.00 Cr..
• For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -228.00 Cr.. The value appears to be declining and may need further review. It has decreased from -157.00 Cr. (Mar 2025) to -228.00 Cr., marking a decrease of 71.00 Cr..
• For Tax %, as of Jun 2025, the value is -19.00%. The value appears to be improving (decreasing) as expected. It has decreased from -5.00% (Mar 2025) to -19.00%, marking a decrease of 14.00%.
• For Net Profit, as of Jun 2025, the value is -186.00 Cr.. The value appears to be declining and may need further review. It has decreased from -149.00 Cr. (Mar 2025) to -186.00 Cr., marking a decrease of 37.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -10.16. The value appears to be declining and may need further review. It has decreased from -8.11 (Mar 2025) to -10.16, marking a decrease of 2.05.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 2:21 pm

Growth

Last Updated: September 5, 2025, 11:55 am

Balance Sheet

Last Updated: November 9, 2025, 2:38 pm

Below is a detailed analysis of the balance sheet data for Omaxe Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 183.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 183.00 Cr..
• For Reserves, as of Mar 2025, the value is -388.00 Cr.. The value appears to be declining and may need further review. It has decreased from 298.00 Cr. (Mar 2024) to -388.00 Cr., marking a decrease of 686.00 Cr..
• For Borrowings, as of Mar 2025, the value is 796.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2024) which recorded 796.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 14,300.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,546.00 Cr. (Mar 2024) to 14,300.00 Cr., marking an increase of 1,754.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 14,891.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 13,822.00 Cr. (Mar 2024) to 14,891.00 Cr., marking an increase of 1,069.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 606.00 Cr.. The value appears strong and on an upward trend. It has increased from 565.00 Cr. (Mar 2024) to 606.00 Cr., marking an increase of 41.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 21.00 Cr.. The value appears to be declining and may need further review. It has decreased from 29.00 Cr. (Mar 2024) to 21.00 Cr., marking a decrease of 8.00 Cr..
• For Other Assets, as of Mar 2025, the value is 14,264.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,228.00 Cr. (Mar 2024) to 14,264.00 Cr., marking an increase of 1,036.00 Cr..
• For Total Assets, as of Mar 2025, the value is 14,891.00 Cr.. The value appears strong and on an upward trend. It has increased from 13,822.00 Cr. (Mar 2024) to 14,891.00 Cr., marking an increase of 1,069.00 Cr..

However, the Borrowings (796.00 Cr.) are higher than the Reserves (-388.00 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Omaxe Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
• For Diluted EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
• For Cash EPS (Rs.), as of Mar 25, the value is -35.45. This value is below the healthy minimum of 3. It has decreased from -19.24 (Mar 24) to -35.45, marking a decrease of 16.21.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.35. It has decreased from 88.26 (Mar 24) to 85.35, marking a decrease of 2.91.
• For PBDIT / Share (Rs.), as of Mar 25, the value is -29.07. This value is below the healthy minimum of 2. It has decreased from -17.64 (Mar 24) to -29.07, marking a decrease of 11.43.
• For PBIT / Share (Rs.), as of Mar 25, the value is -31.08. This value is below the healthy minimum of 0. It has decreased from -20.61 (Mar 24) to -31.08, marking a decrease of 10.47.
• For PBT / Share (Rs.), as of Mar 25, the value is -41.76. This value is below the healthy minimum of 0. It has decreased from -27.74 (Mar 24) to -41.76, marking a decrease of 14.02.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -37.46. This value is below the healthy minimum of 2. It has decreased from -22.20 (Mar 24) to -37.46, marking a decrease of 15.26.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 2. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
• For PBDIT Margin (%), as of Mar 25, the value is -34.06. This value is below the healthy minimum of 10. It has decreased from -19.98 (Mar 24) to -34.06, marking a decrease of 14.08.
• For PBIT Margin (%), as of Mar 25, the value is -36.41. This value is below the healthy minimum of 10. It has decreased from -23.35 (Mar 24) to -36.41, marking a decrease of 13.06.
• For PBT Margin (%), as of Mar 25, the value is -48.92. This value is below the healthy minimum of 10. It has decreased from -31.42 (Mar 24) to -48.92, marking a decrease of 17.50.
• For Net Profit Margin (%), as of Mar 25, the value is -43.89. This value is below the healthy minimum of 5. It has decreased from -25.15 (Mar 24) to -43.89, marking a decrease of 18.74.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -43.94. This value is below the healthy minimum of 8. It has decreased from -24.93 (Mar 24) to -43.94, marking a decrease of 19.01.
• For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -157.76 (Mar 24) to 0.00, marking an increase of 157.76.
• For Return on Capital Employeed (%), as of Mar 25, the value is -61.52. This value is below the healthy minimum of 10. It has decreased from -23.15 (Mar 24) to -61.52, marking a decrease of 38.37.
• For Return On Assets (%), as of Mar 25, the value is -4.61. This value is below the healthy minimum of 5. It has decreased from -2.91 (Mar 24) to -4.61, marking a decrease of 1.70.
• For Long Term Debt / Equity (X), as of Mar 25, the value is -2.43. This value is below the healthy minimum of 0.2. It has decreased from 1.95 (Mar 24) to -2.43, marking a decrease of 4.38.
• For Total Debt / Equity (X), as of Mar 25, the value is -3.62. This value is within the healthy range. It has decreased from 2.86 (Mar 24) to -3.62, marking a decrease of 6.48.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.95, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.16, marking an increase of 0.01.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.19, marking an increase of 0.19.
• For Interest Coverage Ratio (X), as of Mar 25, the value is -2.72. This value is below the healthy minimum of 3. It has decreased from -2.48 (Mar 24) to -2.72, marking a decrease of 0.24.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.51. This value is below the healthy minimum of 3. It has decreased from -2.12 (Mar 24) to -2.51, marking a decrease of 0.39.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,437.16. It has decreased from 1,855.26 (Mar 24) to 1,437.16, marking a decrease of 418.10.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 24) to 0.92, marking a decrease of 0.23.
• For EV / EBITDA (X), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 5. It has increased from -5.75 (Mar 24) to -2.70, marking an increase of 3.05.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
• For Price / BV (X), as of Mar 25, the value is -6.96. This value is below the healthy minimum of 1. It has decreased from 6.50 (Mar 24) to -6.96, marking a decrease of 13.46.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
• For EarningsYield, as of Mar 25, the value is -0.48. This value is below the healthy minimum of 5. It has decreased from -0.24 (Mar 24) to -0.48, marking a decrease of 0.24.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness